JP2010530002A - カリウムチャネルモジュレーターとしての４−（ｎ−アザシクロアルキル）アニリドの誘導体 - Google Patents
カリウムチャネルモジュレーターとしての４−（ｎ−アザシクロアルキル）アニリドの誘導体 Download PDFInfo
- Publication number
- JP2010530002A JP2010530002A JP2010512399A JP2010512399A JP2010530002A JP 2010530002 A JP2010530002 A JP 2010530002A JP 2010512399 A JP2010512399 A JP 2010512399A JP 2010512399 A JP2010512399 A JP 2010512399A JP 2010530002 A JP2010530002 A JP 2010530002A
- Authority
- JP
- Japan
- Prior art keywords
- compound
- alkyl
- cycloalkyl
- chr
- halogen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102000004257 Potassium Channel Human genes 0.000 title claims abstract description 13
- 108020001213 potassium channel Proteins 0.000 title claims abstract description 13
- 150000003931 anilides Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract description 275
- 229910052757 nitrogen Inorganic materials 0.000 claims abstract description 19
- 125000003118 aryl group Chemical group 0.000 claims abstract description 15
- 125000001424 substituent group Chemical group 0.000 claims abstract description 10
- 150000003839 salts Chemical class 0.000 claims abstract description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 7
- 125000004433 nitrogen atom Chemical group N* 0.000 claims abstract description 7
- 230000000694 effects Effects 0.000 claims abstract description 6
- 238000000034 method Methods 0.000 claims abstract description 6
- 239000000651 prodrug Substances 0.000 claims abstract description 6
- 229940002612 prodrug Drugs 0.000 claims abstract description 6
- 150000002148 esters Chemical class 0.000 claims abstract description 5
- 201000010099 disease Diseases 0.000 claims abstract description 3
- 208000035475 disorder Diseases 0.000 claims abstract description 3
- 239000003937 drug carrier Substances 0.000 claims abstract description 3
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 81
- 229910052736 halogen Inorganic materials 0.000 claims description 69
- 150000002367 halogens Chemical class 0.000 claims description 69
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 43
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 30
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 29
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 29
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 29
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 28
- 229910052739 hydrogen Inorganic materials 0.000 claims description 26
- 125000004076 pyridyl group Chemical group 0.000 claims description 26
- 229910052760 oxygen Inorganic materials 0.000 claims description 25
- -1 cyano, methyl Chemical group 0.000 claims description 22
- 125000000217 alkyl group Chemical group 0.000 claims description 21
- 229910052717 sulfur Inorganic materials 0.000 claims description 19
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 18
- 125000000168 pyrrolyl group Chemical group 0.000 claims description 17
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 16
- 125000000392 cycloalkenyl group Chemical group 0.000 claims description 12
- 125000005842 heteroatom Chemical group 0.000 claims description 11
- 125000003342 alkenyl group Chemical group 0.000 claims description 10
- 229910052731 fluorine Inorganic materials 0.000 claims description 10
- 125000002883 imidazolyl group Chemical group 0.000 claims description 10
- 125000001786 isothiazolyl group Chemical group 0.000 claims description 10
- 125000000842 isoxazolyl group Chemical group 0.000 claims description 10
- 125000002971 oxazolyl group Chemical group 0.000 claims description 10
- 125000000335 thiazolyl group Chemical group 0.000 claims description 10
- 239000011203 carbon fibre reinforced carbon Substances 0.000 claims description 9
- 125000000304 alkynyl group Chemical group 0.000 claims description 8
- 125000005412 pyrazyl group Chemical group 0.000 claims description 8
- 229910052799 carbon Inorganic materials 0.000 claims description 7
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 6
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 5
- 239000001257 hydrogen Substances 0.000 claims description 5
- 125000002541 furyl group Chemical group 0.000 claims description 4
- 125000001072 heteroaryl group Chemical group 0.000 claims description 4
- 125000002950 monocyclic group Chemical group 0.000 claims description 4
- 125000001544 thienyl group Chemical group 0.000 claims description 4
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims description 3
- 150000001721 carbon Chemical group 0.000 claims description 3
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 3
- 125000004366 heterocycloalkenyl group Chemical group 0.000 claims description 3
- 229920006395 saturated elastomer Polymers 0.000 claims description 3
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 2
- 230000002265 prevention Effects 0.000 claims description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 6
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000203 mixture Substances 0.000 abstract description 60
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 63
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 30
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 24
- 125000001434 methanylylidene group Chemical group [H]C#[*] 0.000 description 21
- 230000015572 biosynthetic process Effects 0.000 description 20
- 238000003786 synthesis reaction Methods 0.000 description 20
- 239000012267 brine Substances 0.000 description 19
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 19
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 18
- 239000012044 organic layer Substances 0.000 description 15
- 239000011541 reaction mixture Substances 0.000 description 15
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 12
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 11
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 10
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 10
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- 239000000872 buffer Substances 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- ZEMZPXWZVTUONV-UHFFFAOYSA-N 2-(2-dicyclohexylphosphanylphenyl)-n,n-dimethylaniline Chemical group CN(C)C1=CC=CC=C1C1=CC=CC=C1P(C1CCCCC1)C1CCCCC1 ZEMZPXWZVTUONV-UHFFFAOYSA-N 0.000 description 8
- 150000001412 amines Chemical group 0.000 description 8
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 8
- PCOBBVZJEWWZFR-UHFFFAOYSA-N ezogabine Chemical compound C1=C(N)C(NC(=O)OCC)=CC=C1NCC1=CC=C(F)C=C1 PCOBBVZJEWWZFR-UHFFFAOYSA-N 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- UWYZHKAOTLEWKK-UHFFFAOYSA-N 1,2,3,4-tetrahydroisoquinoline Chemical compound C1=CC=C2CNCCC2=C1 UWYZHKAOTLEWKK-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 229910052786 argon Inorganic materials 0.000 description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
- 229960003312 retigabine Drugs 0.000 description 6
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 6
- NBZLULAOPCARMB-UHFFFAOYSA-N 1,3-dichloro-4-phenylbut-3-en-2-one Chemical compound ClCC(=O)C(Cl)=CC1=CC=CC=C1 NBZLULAOPCARMB-UHFFFAOYSA-N 0.000 description 5
- 108091006146 Channels Proteins 0.000 description 5
- 239000007983 Tris buffer Substances 0.000 description 5
- 230000004907 flux Effects 0.000 description 5
- 239000003999 initiator Substances 0.000 description 5
- 230000028161 membrane depolarization Effects 0.000 description 5
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- GQHTUMJGOHRCHB-UHFFFAOYSA-N 2,3,4,6,7,8,9,10-octahydropyrimido[1,2-a]azepine Chemical compound C1CCCCN2CCCN=C21 GQHTUMJGOHRCHB-UHFFFAOYSA-N 0.000 description 4
- BUTKIHRNYUEGKB-UHFFFAOYSA-N 3,3-dimethylbutanoyl chloride Chemical compound CC(C)(C)CC(Cl)=O BUTKIHRNYUEGKB-UHFFFAOYSA-N 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 4
- 125000004429 atom Chemical group 0.000 description 4
- 125000004970 halomethyl group Chemical group 0.000 description 4
- FGDZQCVHDSGLHJ-UHFFFAOYSA-M rubidium chloride Chemical compound [Cl-].[Rb+] FGDZQCVHDSGLHJ-UHFFFAOYSA-M 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 108010006746 KCNQ2 Potassium Channel Proteins 0.000 description 3
- 102100034354 Potassium voltage-gated channel subfamily KQT member 2 Human genes 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 125000002619 bicyclic group Chemical group 0.000 description 3
- 206010015037 epilepsy Diseases 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 229910052763 palladium Inorganic materials 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 239000011534 wash buffer Substances 0.000 description 3
- WOTVKLYMZOREFJ-UHFFFAOYSA-N 6-(trifluoromethyl)-1,2,3,4-tetrahydroisoquinoline Chemical compound C1NCCC2=CC(C(F)(F)F)=CC=C21 WOTVKLYMZOREFJ-UHFFFAOYSA-N 0.000 description 2
- IGFFEMNFESMQQW-UHFFFAOYSA-N 6-fluoro-1,2,3,4-tetrahydroisoquinoline Chemical compound C1NCCC2=CC(F)=CC=C21 IGFFEMNFESMQQW-UHFFFAOYSA-N 0.000 description 2
- JLTDJTHDQAWBAV-UHFFFAOYSA-N N,N-dimethylaniline Chemical compound CN(C)C1=CC=CC=C1 JLTDJTHDQAWBAV-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- HTZCNXWZYVXIMZ-UHFFFAOYSA-M benzyl(triethyl)azanium;chloride Chemical compound [Cl-].CC[N+](CC)(CC)CC1=CC=CC=C1 HTZCNXWZYVXIMZ-UHFFFAOYSA-M 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 239000013592 cell lysate Substances 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- 239000012160 loading buffer Substances 0.000 description 2
- VURSUSFXXYBXGZ-UHFFFAOYSA-N n-[2-(3,4-dihydro-1h-isoquinolin-2-yl)-4,6-dimethoxypyrimidin-5-yl]-3,3-dimethylbutanamide Chemical compound COC1=C(NC(=O)CC(C)(C)C)C(OC)=NC(N2CC3=CC=CC=C3CC2)=N1 VURSUSFXXYBXGZ-UHFFFAOYSA-N 0.000 description 2
- MWLAWFJNXCNHPL-UHFFFAOYSA-N n-[4,6-dimethoxy-2-[6-(trifluoromethyl)-3,4-dihydro-1h-isoquinolin-2-yl]pyrimidin-5-yl]-3,3-dimethylbutanamide Chemical compound COC1=C(NC(=O)CC(C)(C)C)C(OC)=NC(N2CC3=CC=C(C=C3CC2)C(F)(F)F)=N1 MWLAWFJNXCNHPL-UHFFFAOYSA-N 0.000 description 2
- XLOPSBBUBVXOIL-UHFFFAOYSA-N n-[6-(3,4-dihydro-1h-isoquinolin-2-yl)-2,4-dimethylpyridin-3-yl]-3,3-dimethylbutanamide Chemical compound CC1=C(NC(=O)CC(C)(C)C)C(C)=CC(N2CC3=CC=CC=C3CC2)=N1 XLOPSBBUBVXOIL-UHFFFAOYSA-N 0.000 description 2
- 229910052759 nickel Inorganic materials 0.000 description 2
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- WJKHJLXJJJATHN-UHFFFAOYSA-N triflic anhydride Chemical compound FC(F)(F)S(=O)(=O)OS(=O)(=O)C(F)(F)F WJKHJLXJJJATHN-UHFFFAOYSA-N 0.000 description 2
- FSYHJEBPLDNXAM-UHFFFAOYSA-N 2,4-dimethylpyridin-3-amine Chemical compound CC1=CC=NC(C)=C1N FSYHJEBPLDNXAM-UHFFFAOYSA-N 0.000 description 1
- XSZKVKMGSAAAJZ-UHFFFAOYSA-N 2,4-dimethylpyridine-3-carboxylic acid Chemical compound CC1=CC=NC(C)=C1C(O)=O XSZKVKMGSAAAJZ-UHFFFAOYSA-N 0.000 description 1
- OZJZCCMIOZPPIT-UHFFFAOYSA-N 2-(2-methoxyethoxy)acetyl chloride Chemical compound COCCOCC(Cl)=O OZJZCCMIOZPPIT-UHFFFAOYSA-N 0.000 description 1
- DGHSLOHHVSPBIK-UHFFFAOYSA-N 2-(3,4-dihydro-1h-isoquinolin-2-yl)-4,6-dimethoxypyrimidin-5-amine Chemical compound COC1=C(N)C(OC)=NC(N2CC3=CC=CC=C3CC2)=N1 DGHSLOHHVSPBIK-UHFFFAOYSA-N 0.000 description 1
- CPCHRVAFINZGOY-UHFFFAOYSA-N 2-(3,4-dihydro-1h-isoquinolin-2-yl)-4,6-dimethylpyrimidin-5-amine Chemical compound CC1=C(N)C(C)=NC(N2CC3=CC=CC=C3CC2)=N1 CPCHRVAFINZGOY-UHFFFAOYSA-N 0.000 description 1
- RUEFAABHFWICOC-UHFFFAOYSA-N 2-(3,4-dihydro-1h-isoquinolin-2-yl)-4,6-dimethylpyrimidine-5-carboxylic acid Chemical compound CC1=C(C(O)=O)C(C)=NC(N2CC3=CC=CC=C3CC2)=N1 RUEFAABHFWICOC-UHFFFAOYSA-N 0.000 description 1
- RXLJXPPVVNGJCS-UHFFFAOYSA-N 2-(4,6-dimethoxy-5-nitropyrimidin-2-yl)-3,4-dihydro-1h-isoquinoline Chemical compound COC1=C([N+]([O-])=O)C(OC)=NC(N2CC3=CC=CC=C3CC2)=N1 RXLJXPPVVNGJCS-UHFFFAOYSA-N 0.000 description 1
- UOGPJRCEIZZIAO-UHFFFAOYSA-N 2-(4,6-dimethoxy-5-nitropyrimidin-2-yl)-6-(trifluoromethyl)-3,4-dihydro-1h-isoquinoline Chemical compound COC1=C([N+]([O-])=O)C(OC)=NC(N2CC3=CC=C(C=C3CC2)C(F)(F)F)=N1 UOGPJRCEIZZIAO-UHFFFAOYSA-N 0.000 description 1
- CKMCVIMYBWEVKX-UHFFFAOYSA-N 2-(trifluoromethyl)-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidine Chemical compound C1NCCC2=NC(C(F)(F)F)=NC=C21 CKMCVIMYBWEVKX-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- KUCWUAFNGCMZDB-UHFFFAOYSA-N 2-amino-3-nitrophenol Chemical compound NC1=C(O)C=CC=C1[N+]([O-])=O KUCWUAFNGCMZDB-UHFFFAOYSA-N 0.000 description 1
- FETZNGVNMWWJPO-UHFFFAOYSA-N 2-chloro-4,6-dimethoxy-5-nitropyrimidine Chemical compound COC1=NC(Cl)=NC(OC)=C1[N+]([O-])=O FETZNGVNMWWJPO-UHFFFAOYSA-N 0.000 description 1
- PBEKEFWBLFBSGQ-UHFFFAOYSA-N 2-chloro-4,6-dimethoxypyrimidine Chemical compound COC1=CC(OC)=NC(Cl)=N1 PBEKEFWBLFBSGQ-UHFFFAOYSA-N 0.000 description 1
- 125000004211 3,5-difluorophenyl group Chemical group [H]C1=C(F)C([H])=C(*)C([H])=C1F 0.000 description 1
- YVKYZZSGAOUFGK-UHFFFAOYSA-N 3-(trifluoromethyl)-5,6,7,8-tetrahydro-1,6-naphthyridine Chemical compound C1CNCC2=CC(C(F)(F)F)=CN=C21 YVKYZZSGAOUFGK-UHFFFAOYSA-N 0.000 description 1
- PAUMLQOQTZUUGQ-UHFFFAOYSA-N 4,6-dimethoxy-2-[6-(trifluoromethyl)-3,4-dihydro-1h-isoquinolin-2-yl]pyrimidin-5-amine Chemical compound COC1=C(N)C(OC)=NC(N2CC3=CC=C(C=C3CC2)C(F)(F)F)=N1 PAUMLQOQTZUUGQ-UHFFFAOYSA-N 0.000 description 1
- STXKJIIHKFGUCY-UHFFFAOYSA-N 5,6,7,8-tetrahydropyrido[4,3-d]pyrimidine Chemical compound C1=NC=C2CNCCC2=N1 STXKJIIHKFGUCY-UHFFFAOYSA-N 0.000 description 1
- YSICEHWFFMXFAP-UHFFFAOYSA-N 6-(trifluoromethyl)-1,2,3,4-tetrahydroisoquinoline;hydrochloride Chemical compound Cl.C1NCCC2=CC(C(F)(F)F)=CC=C21 YSICEHWFFMXFAP-UHFFFAOYSA-N 0.000 description 1
- FLDDNTAAWZHAOT-UHFFFAOYSA-N 6-bromo-2,4-dimethylpyridin-3-amine Chemical compound CC1=CC(Br)=NC(C)=C1N FLDDNTAAWZHAOT-UHFFFAOYSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 208000008882 Benign Neonatal Epilepsy Diseases 0.000 description 1
- 206010067866 Benign familial neonatal convulsions Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- KDXKERNSBIXSRK-RXMQYKEDSA-N D-lysine Chemical compound NCCCC[C@@H](N)C(O)=O KDXKERNSBIXSRK-RXMQYKEDSA-N 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 101000913968 Ipomoea purpurea Chalcone synthase C Proteins 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 101000907988 Petunia hybrida Chalcone-flavanone isomerase C Proteins 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 238000001479 atomic absorption spectroscopy Methods 0.000 description 1
- 239000005441 aurora Substances 0.000 description 1
- 201000003452 benign familial neonatal epilepsy Diseases 0.000 description 1
- 201000010295 benign neonatal seizures Diseases 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 125000004618 benzofuryl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- DNSISZSEWVHGLH-UHFFFAOYSA-N butanamide Chemical compound CCCC(N)=O DNSISZSEWVHGLH-UHFFFAOYSA-N 0.000 description 1
- 238000011088 calibration curve Methods 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 125000002837 carbocyclic group Chemical group 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 125000004093 cyano group Chemical group *C#N 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 208000037765 diseases and disorders Diseases 0.000 description 1
- DIZHKKYVLBSXAW-UHFFFAOYSA-N ethyl 2,4-dimethylpyridine-3-carboxylate Chemical compound CCOC(=O)C1=C(C)C=CN=C1C DIZHKKYVLBSXAW-UHFFFAOYSA-N 0.000 description 1
- TYHAINZSDRJUNN-UHFFFAOYSA-N ethyl 2-(3,4-dihydro-1h-isoquinolin-2-yl)-4,6-dimethylpyrimidine-5-carboxylate Chemical compound N1=C(C)C(C(=O)OCC)=C(C)N=C1N1CC2=CC=CC=C2CC1 TYHAINZSDRJUNN-UHFFFAOYSA-N 0.000 description 1
- YMCDYRGMTRCAPZ-UHFFFAOYSA-N ethyl 2-acetyl-3-oxobutanoate Chemical compound CCOC(=O)C(C(C)=O)C(C)=O YMCDYRGMTRCAPZ-UHFFFAOYSA-N 0.000 description 1
- QWWCHVHQVYFMJU-UHFFFAOYSA-N ethyl 2-chloro-4,6-dimethylpyrimidine-5-carboxylate Chemical compound CCOC(=O)C1=C(C)N=C(Cl)N=C1C QWWCHVHQVYFMJU-UHFFFAOYSA-N 0.000 description 1
- KJWOQDPSBKFTPF-UHFFFAOYSA-N ethyl 4,6-dimethyl-2-oxo-1h-pyrimidine-5-carboxylate Chemical compound CCOC(=O)C1=C(C)N=C(O)N=C1C KJWOQDPSBKFTPF-UHFFFAOYSA-N 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 125000005059 halophenyl group Chemical group 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
- 125000005956 isoquinolyl group Chemical group 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- UCXZIVSAIVTKNT-UHFFFAOYSA-N n-(6-bromo-2,4-dimethylpyridin-3-yl)-2-(2-methoxyethoxy)acetamide Chemical compound COCCOCC(=O)NC1=C(C)C=C(Br)N=C1C UCXZIVSAIVTKNT-UHFFFAOYSA-N 0.000 description 1
- ANOAORXOYSFENG-UHFFFAOYSA-N n-(6-bromo-2,4-dimethylpyridin-3-yl)-3,3-dimethylbutanamide Chemical compound CC1=CC(Br)=NC(C)=C1NC(=O)CC(C)(C)C ANOAORXOYSFENG-UHFFFAOYSA-N 0.000 description 1
- PBOIRYABEXSZSY-UHFFFAOYSA-N n-[2,4-dimethyl-6-[2-(trifluoromethyl)-7,8-dihydro-5h-pyrido[4,3-d]pyrimidin-6-yl]pyridin-3-yl]-3,3-dimethylbutanamide Chemical compound CC1=C(NC(=O)CC(C)(C)C)C(C)=CC(N2CC3=CN=C(N=C3CC2)C(F)(F)F)=N1 PBOIRYABEXSZSY-UHFFFAOYSA-N 0.000 description 1
- GBFYNQFQYQWOSP-UHFFFAOYSA-N n-[2,4-dimethyl-6-[6-(trifluoromethyl)-3,4-dihydro-1h-isoquinolin-2-yl]pyridin-3-yl]-3,3-dimethylbutanamide Chemical compound CC1=C(NC(=O)CC(C)(C)C)C(C)=CC(N2CC3=CC=C(C=C3CC2)C(F)(F)F)=N1 GBFYNQFQYQWOSP-UHFFFAOYSA-N 0.000 description 1
- OOLWEKXOJCPGBH-UHFFFAOYSA-N n-[2,4-dimethyl-6-[7-(trifluoromethyl)-3,4-dihydro-1h-isoquinolin-2-yl]pyridin-3-yl]-3,3-dimethylbutanamide Chemical compound CC1=C(NC(=O)CC(C)(C)C)C(C)=CC(N2CC3=CC(=CC=C3CC2)C(F)(F)F)=N1 OOLWEKXOJCPGBH-UHFFFAOYSA-N 0.000 description 1
- PWQDNLQJTIZBLA-UHFFFAOYSA-N n-[2-(3,4-dihydro-1h-isoquinolin-2-yl)-4,6-dimethylpyrimidin-5-yl]-3,3-dimethylbutanamide Chemical compound CC1=C(NC(=O)CC(C)(C)C)C(C)=NC(N2CC3=CC=CC=C3CC2)=N1 PWQDNLQJTIZBLA-UHFFFAOYSA-N 0.000 description 1
- HPGPGROIZDQSSL-UHFFFAOYSA-N n-[6-(6-fluoro-3,4-dihydro-1h-isoquinolin-2-yl)-2,4-dimethylpyridin-3-yl]-3,3-dimethylbutanamide Chemical compound CC1=C(NC(=O)CC(C)(C)C)C(C)=CC(N2CC3=CC=C(F)C=C3CC2)=N1 HPGPGROIZDQSSL-UHFFFAOYSA-N 0.000 description 1
- HGFNQMVYAFROEK-UHFFFAOYSA-N n-[6-(7,8-dihydro-5h-pyrido[4,3-d]pyrimidin-6-yl)-2,4-dimethylpyridin-3-yl]-3,3-dimethylbutanamide Chemical compound CC1=C(NC(=O)CC(C)(C)C)C(C)=CC(N2CC3=CN=CN=C3CC2)=N1 HGFNQMVYAFROEK-UHFFFAOYSA-N 0.000 description 1
- 208000004296 neuralgia Diseases 0.000 description 1
- 208000021722 neuropathic pain Diseases 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 125000005493 quinolyl group Chemical group 0.000 description 1
- 239000012429 reaction media Substances 0.000 description 1
- 230000036390 resting membrane potential Effects 0.000 description 1
- 125000006413 ring segment Chemical group 0.000 description 1
- 229910052701 rubidium Inorganic materials 0.000 description 1
- IGLNJRXAVVLDKE-UHFFFAOYSA-N rubidium atom Chemical compound [Rb] IGLNJRXAVVLDKE-UHFFFAOYSA-N 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- SEDZOYHHAIAQIW-UHFFFAOYSA-N trimethylsilyl azide Chemical compound C[Si](C)(C)N=[N+]=[N-] SEDZOYHHAIAQIW-UHFFFAOYSA-N 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US93439607P | 2007-06-13 | 2007-06-13 | |
| US12/138,251 US8367684B2 (en) | 2007-06-13 | 2008-06-12 | Derivatives of 4-(N-azacycloalkyl) anilides as potassium channel modulators |
| PCT/US2008/066984 WO2008157404A2 (en) | 2007-06-13 | 2008-06-13 | Derivatives of 4-(n-azacycloalkyl) anilides as potassium channel modulators |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010530002A true JP2010530002A (ja) | 2010-09-02 |
| JP2010530002A5 JP2010530002A5 (https=) | 2012-07-19 |
Family
ID=40137141
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010512399A Pending JP2010530002A (ja) | 2007-06-13 | 2008-06-13 | カリウムチャネルモジュレーターとしての４−（ｎ−アザシクロアルキル）アニリドの誘導体 |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US8367684B2 (https=) |
| EP (1) | EP2170861B1 (https=) |
| JP (1) | JP2010530002A (https=) |
| KR (1) | KR20100018618A (https=) |
| CN (1) | CN101868451A (https=) |
| AU (1) | AU2008266009B2 (https=) |
| BR (1) | BRPI0812564A2 (https=) |
| CA (1) | CA2689208A1 (https=) |
| DK (1) | DK2170861T3 (https=) |
| ES (1) | ES2392774T3 (https=) |
| HR (1) | HRP20120857T1 (https=) |
| MX (1) | MX2009013581A (https=) |
| PL (1) | PL2170861T3 (https=) |
| PT (1) | PT2170861E (https=) |
| RU (1) | RU2010100893A (https=) |
| SI (1) | SI2170861T1 (https=) |
| TW (1) | TW200914452A (https=) |
| WO (1) | WO2008157404A2 (https=) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2010535244A (ja) * | 2007-08-01 | 2010-11-18 | バレアント ファーマシューティカルズ インターナショナル | カリウムチャネル調節因子としてのナフチリジン誘導体 |
| JP2010536771A (ja) * | 2007-08-13 | 2010-12-02 | バレアント ファーマシューティカルズ インターナショナル | カリウムチャネルモジュレーターとしての５−アミノ−４，６−二置換インドールおよび５−アミノ−４，６−二置換インドリンの誘導体 |
| JP2021525241A (ja) * | 2018-05-22 | 2021-09-24 | シャンハイ ジムン バイオファーマ, インコーポレーテッドShanghai Zhimeng Biopharma Inc. | カリウムチャネル調節剤としてのｐ−ジアミノベンゼン誘導体、その製造方法およびその医薬における使用 |
| JP2025504538A (ja) * | 2022-01-25 | 2025-02-12 | シャンハイ ジムン バイオファーマ，インコーポレーテッド | カリウムチャネル調節剤としてのアミド系化合物およびその製造と使用 |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20120115900A1 (en) | 2009-04-21 | 2012-05-10 | Neurosearch A/S | Substituted naphthyridine derivatives and their medical use |
| AU2011275393B2 (en) * | 2010-07-08 | 2014-04-10 | Pfizer Inc. | Piperidinyl pyrimidine amides as Kv7 potassium channel openers |
| RU2014144951A (ru) | 2012-04-10 | 2016-06-10 | Сумитомо Дайниппон Фарма Ко., Лтд. | Новое 1-замещенное производное индазола |
| CN108250128A (zh) * | 2012-09-27 | 2018-07-06 | 江苏先声药业有限公司 | 作为钾通道调节剂的化合物 |
| CN107835649B (zh) | 2015-07-07 | 2021-03-23 | 高露洁-棕榄公司 | 口腔护理器具和用于口腔护理器具的单丝刷毛 |
| TW202333693A (zh) * | 2021-12-31 | 2023-09-01 | 大陸商上海翰森生物醫藥科技有限公司 | 苯并哌啶衍生物調節劑、其製備方法和應用 |
Citations (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2000513014A (ja) * | 1997-03-27 | 2000-10-03 | ユハン・コーポレーション | 新規ピリミジン誘導体およびその製造方法 |
| WO2003066099A1 (en) * | 2002-02-05 | 2003-08-14 | Yamanouchi Pharmaceutical Co., Ltd. | 2,4,6-triamino-1,3,5-triazine derivative |
| JP2004002309A (ja) * | 2002-02-12 | 2004-01-08 | Pfizer Inc | 非ペプチドＧｎＲＨ剤、医薬組成物、及びそれらの使用方法 |
| JP2004518724A (ja) * | 2001-02-07 | 2004-06-24 | オーソーマクニール ファーマシューティカル， インコーポレイテッド | ピリドアリールフェニル・オキサゾリジノン抗菌剤、および関連の組成物および方法 |
| WO2005066171A1 (en) * | 2003-12-24 | 2005-07-21 | Renovis, Inc. | Bicycloheteroarylamine compounds as ion channel ligands and uses thereof |
| WO2006006741A1 (ja) * | 2004-07-15 | 2006-01-19 | Japan Tobacco Inc. | 縮合ベンズアミド化合物及びバニロイド受容体１型(ｖｒ１)活性阻害剤 |
| WO2006029623A1 (en) * | 2004-09-13 | 2006-03-23 | H. Lundbeck A/S | Substituted aniline derivatives |
| WO2006034402A2 (en) * | 2004-09-21 | 2006-03-30 | Synta Pharmaceutical Corp. | Compounds for inflammation and immune-related uses |
| WO2006092143A1 (en) * | 2005-03-03 | 2006-09-08 | H. Lundbeck A/S | Substituted pyridine derivatives |
| WO2007050348A2 (en) * | 2005-10-21 | 2007-05-03 | Merck & Co., Inc. | Potassium channel inhibitors |
| WO2008024398A2 (en) * | 2006-08-23 | 2008-02-28 | Valeant Pharmaceuticals International | Derivatives of 4-(n-azacycloalkyl) anilides as potassium channel modulators |
Family Cites Families (79)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4181803A (en) * | 1973-12-14 | 1980-01-01 | Eisai Co., Ltd. | Propiophenone derivatives and preparation thereof |
| DE3337593A1 (de) | 1982-10-27 | 1984-05-03 | Degussa Ag, 6000 Frankfurt | 2-amino-3-acylamino-6-benzylamino-pyridin-derivate mit antiepileptischer wirkung |
| ATE25078T1 (de) * | 1982-10-27 | 1987-02-15 | Degussa | 2-amino-3-acylamino-6-benzylamino-pyridinderivate mit anti-epileptischer wirkung. |
| DE3665538D1 (en) | 1985-01-23 | 1989-10-19 | Asta Pharma Ag | Synergistic combination of flupirtin and non-steroidal anti-phlogistics |
| EP0193056B1 (de) * | 1985-02-23 | 1989-06-07 | ASTA Pharma Aktiengesellschaft | Kombination von Flupirtin und anticholinergisch wirkenden Spasmolytika |
| DE3604575A1 (de) | 1985-02-23 | 1986-08-28 | Degussa Ag, 6000 Frankfurt | Kombination von flupirtin und anticholinergisch wirkenden spasmolytika |
| JP2583067B2 (ja) * | 1987-08-04 | 1997-02-19 | 住友化学工業株式会社 | モノアゾ化合物およびそれを用いて疎水性繊維材料を染色または捺染する方法 |
| GB8800199D0 (en) * | 1988-01-06 | 1988-02-10 | Beecham Group Plc | Pharmaceutical preparation |
| MC2029A1 (fr) | 1988-05-16 | 1990-04-25 | Asta Pharma Ag | (n-heterocyclyl)-3 diamino-2,6 pyridines substituees et leurs n-oxydes,preparation de ces composes et leur application comme medicaments |
| US5629307A (en) * | 1989-10-20 | 1997-05-13 | Olney; John W. | Use of ibogaine in reducing excitotoxic brain damage |
| US6004945A (en) * | 1990-05-10 | 1999-12-21 | Fukunaga; Atsuo F. | Use of adenosine compounds to relieve pain |
| IN172468B (https=) * | 1990-07-14 | 1993-08-14 | Asta Medica Ag | |
| US5643921A (en) * | 1990-09-26 | 1997-07-01 | E.R. Squibb & Sons, Inc. | Cardiopulmonary bypass and organ transplant using a potassium channel activator |
| US5234947A (en) * | 1991-11-07 | 1993-08-10 | New York University | Potassium channel activating compounds and methods of use thereof |
| DE4200259A1 (de) * | 1992-01-08 | 1993-07-15 | Asta Medica Ag | Neue 1,2,4-triaminobenzol-derivate und verfahren zu deren herstellung |
| US5262419A (en) * | 1992-06-11 | 1993-11-16 | E. R. Squibb & Sons, Inc. | Method for the prophylaxis and/or treatment of ulcerative gastrointestinal conditions using a potassium channel activator |
| CA2115792C (en) * | 1993-03-05 | 2005-11-01 | David J. Mayer | Method for the treatment of pain |
| US5428039A (en) * | 1994-02-20 | 1995-06-27 | The Center For Innovative Technology | Method for electively achieving reversible hyperpolarized cardiac arrest |
| JPH10503501A (ja) * | 1994-08-03 | 1998-03-31 | アスタ メディカ アクチエンゲゼルシャフト | 抗喘息、抗アレルギー、抗炎症及び免疫修飾作用を有するインドール、インダゾール、ピリドピロール及びピリドピラゾール誘導体 |
| JP4097285B2 (ja) * | 1994-09-22 | 2008-06-11 | リチャード・アラン・スミス | 種々の頑固な疾患の治療のための医薬の製造に有用な組成物 |
| US5679706A (en) * | 1994-09-30 | 1997-10-21 | Bristol-Myers Squibb Company | Combination of a potassium channel activator and an antiarrhythmic agent |
| WO1996019233A2 (en) * | 1994-12-12 | 1996-06-27 | Omeros Medical Systems, Inc. | Irrigation solution and method for inhibition of pain, inflammation and spasm |
| DE19539861A1 (de) * | 1995-10-26 | 1997-04-30 | Asta Medica Ag | Verwendung von 4-Amino-4-(4-fluorbenzylamino)-1-ethoxy-carbonylaminobenzen zur Prophylaxe und Behandlung der Folgen der akuten und chronischen zerebralen Minderdurchblutung sowie neurodegenerativer Erkrankungen |
| DE19701694A1 (de) * | 1997-01-20 | 1998-07-23 | Asta Medica Ag | Neue Modifikationen des 2-Amino-4-(4-fluorbenzylamino)-l-ethoxycarbonyl-aminobenzen sowie Verfahren zu ihrer Herstellung |
| US5760007A (en) * | 1997-07-16 | 1998-06-02 | Ortho Pharmaceutical Corporation | Anticonvulsant derivatives useful in treating neuropathic pain |
| AU8561298A (en) * | 1997-08-08 | 1999-03-01 | Chugai Seiyaku Kabushiki Kaisha | Remedies for complications of diabetes |
| US6593335B1 (en) * | 1997-12-18 | 2003-07-15 | Abbott Laboratories | Potassium channel openers |
| US6265417B1 (en) * | 1997-12-18 | 2001-07-24 | Abbott Laboratories | Potassium channel openers |
| US6211171B1 (en) * | 1998-05-19 | 2001-04-03 | Dalhousie University | Use of antidepressants for local analgesia |
| JP3441970B2 (ja) | 1998-06-30 | 2003-09-02 | 株式会社サミー | 豆腐の製造方法及び製造装置 |
| JP2000143510A (ja) | 1998-11-16 | 2000-05-23 | Taisho Pharmaceut Co Ltd | 外用組成物 |
| BR9916162A (pt) * | 1998-12-14 | 2001-09-04 | Cellegy Pharma Inc | Composição e método para o tratamento de um distúrbio anorretal e para controlar a dor associada com o mesmo |
| US6281211B1 (en) * | 1999-02-04 | 2001-08-28 | Euro-Celtique S.A. | Substituted semicarbazides and the use thereof |
| GB9903476D0 (en) * | 1999-02-17 | 1999-04-07 | Zeneca Ltd | Therapeutic agents |
| US6451857B1 (en) * | 1999-03-10 | 2002-09-17 | Warner-Lambert Company | Analgesic compositions comprising anti-epileptic compounds and methods of using same |
| AU766648B2 (en) | 1999-03-17 | 2003-10-23 | Axys Pharmaceuticals, Inc. | Compounds and methods for modulation of estrogen receptors |
| AT409083B (de) | 1999-04-01 | 2002-05-27 | Sanochemia Pharmazeutika Ag | Pharmazeutische, tolperison enthaltende zubereitung zur oralen verabreichung |
| US6610324B2 (en) | 1999-04-07 | 2003-08-26 | The Mclean Hospital Corporation | Flupirtine in the treatment of fibromyalgia and related conditions |
| GB9915414D0 (en) | 1999-07-01 | 1999-09-01 | Glaxo Group Ltd | Medical use |
| PT1200073E (pt) | 1999-07-06 | 2007-03-30 | Lilly Co Eli | Antagonistas selectivos do receptor de iglur5 para o tratamento de enxaqueca |
| US6472165B1 (en) | 1999-08-03 | 2002-10-29 | Arzneimittelwerk Dresden Gmbh | Modulatory binding site in potassium channels for screening and finding new active ingredients |
| US6495550B2 (en) * | 1999-08-04 | 2002-12-17 | Icagen, Inc. | Pyridine-substituted benzanilides as potassium ion channel openers |
| ATE380176T1 (de) * | 1999-08-04 | 2007-12-15 | Icagen Inc | Benzanilide als öffner des kaliumkanals |
| EP1200086A4 (en) * | 1999-08-04 | 2009-05-27 | Icagen Inc | THERAPEUTIC OR PROPHYLACTIC METHODS OF PAIN AND ANXIETY |
| US6117900A (en) * | 1999-09-27 | 2000-09-12 | Asta Medica Aktiengesellschaft | Use of retigabine for the treatment of neuropathic pain |
| US6383511B1 (en) * | 1999-10-25 | 2002-05-07 | Epicept Corporation | Local prevention or amelioration of pain from surgically closed wounds |
| US6538004B2 (en) * | 2000-03-03 | 2003-03-25 | Abbott Laboratories | Tricyclic dihydropyrazolone and tricyclic dihydroisoxazolone potassium channel openers |
| US20020015730A1 (en) * | 2000-03-09 | 2002-02-07 | Torsten Hoffmann | Pharmaceutical formulations and method for making |
| US6348486B1 (en) * | 2000-10-17 | 2002-02-19 | American Home Products Corporation | Methods for modulating bladder function |
| US6589986B2 (en) * | 2000-12-20 | 2003-07-08 | Wyeth | Methods of treating anxiety disorders |
| US6469042B1 (en) * | 2001-02-20 | 2002-10-22 | Bristol-Myers Squibb Company | Fluoro oxindole derivatives as modulators if KCNQ potassium channels |
| US20020183395A1 (en) * | 2001-04-04 | 2002-12-05 | Wyeth | Methods for treating hyperactive gastric motility |
| GB0121214D0 (en) | 2001-08-31 | 2001-10-24 | Btg Int Ltd | Synthetic method |
| US6831087B2 (en) * | 2001-11-09 | 2004-12-14 | Hoffmann-La Roche Inc. | Pyridine substituted isoquinoline derivatives |
| WO2003097586A1 (en) | 2002-05-17 | 2003-11-27 | Janssen Pharmaceutica N.V. | Aminotetralin-derived urea modulators of vanilloid vr1 receptor |
| WO2003106454A1 (en) | 2002-06-12 | 2003-12-24 | Orchid Chemicals & Pharmaceuticals Ltd | 1h-isoquinoline-oxazolidinone derivaties and their use as antibacterial agents |
| AUPS312602A0 (en) * | 2002-06-21 | 2002-07-18 | James Cook University | Organ arrest, protection, preservation and recovery |
| US7419981B2 (en) * | 2002-08-15 | 2008-09-02 | Pfizer Inc. | Synergistic combinations of an alpha-2-delta ligand and a cGMP phosphodieterse 5 inhibitor |
| US7045551B2 (en) * | 2002-11-22 | 2006-05-16 | Bristol-Myers Squibb Company | 1-aryl-2-hydroxyethyl amides as potassium channel openers |
| ATE488231T1 (de) * | 2002-12-23 | 2010-12-15 | Icagen Inc | Quinazolinone als kaliumkanalmodulatoren |
| ES2282701T3 (es) | 2002-12-27 | 2007-10-16 | H. Lundbeck A/S | Derivados de 1,2,4-triaminobenceno utiles para tratar trastornos del sistema nervioso central. |
| EP1606247A1 (en) | 2003-03-14 | 2005-12-21 | H. Lundbeck A/S | Substituted aniline derivatives |
| WO2004082677A1 (en) | 2003-03-21 | 2004-09-30 | H. Lundbeck A/S | Substituted p-diaminobenzene derivatives |
| MXPA05010174A (es) | 2003-04-25 | 2005-11-08 | Lundbeck & Co As H | Derivados de indol e indolina sustituidos. |
| WO2004105795A1 (en) | 2003-05-27 | 2004-12-09 | Altana Pharma Ag | Pharmaceutical combinations of a proton pump inhibitor and a compound which modifies gastrointestinal motility |
| WO2005007628A1 (en) * | 2003-07-11 | 2005-01-27 | Bristol-Myers Squibb Company | Tetrahydroquinoline derivatives as cannabinoid receptor modulators |
| JP2007505142A (ja) * | 2003-09-10 | 2007-03-08 | セダーズ−シナイ メディカル センター | 血液脳関門を通過する薬剤のカリウムチャネル媒介性送達 |
| US20050089559A1 (en) * | 2003-10-23 | 2005-04-28 | Istvan Szelenyi | Combinations of potassium channel openers and sodium channel inhibitors or sodium channel-influencing active compounds for treating pains |
| DE10359335A1 (de) | 2003-10-23 | 2005-05-25 | Viatris Gmbh & Co. Kg | Kombinationen aus Kaliumkanalöffnern und Natriumkanalinhibitoren oder Natriumkanal beeinflussenden Wirkstoffen zur Behandlung von Schmerzzuständen |
| ES2235626B1 (es) | 2003-11-10 | 2006-11-01 | Almirall Prodesfarma, S.A. | Formas de administracion masticables, no comprimidas dosificadas individualmente. |
| TWI349666B (en) | 2004-03-12 | 2011-10-01 | Lundbeck & Co As H | Substituted morpholine and thiomorpholine derivatives |
| AU2005233642A1 (en) | 2004-04-13 | 2005-10-27 | Astellas Pharma Inc. | Polycyclic pyridines as potassium ion channel modulators |
| RU2006139930A (ru) * | 2004-05-03 | 2008-06-10 | Дюк Юниверсити (Сша/Сша) (Us) | Составы для содействия снижению веса |
| CA2589001A1 (en) | 2004-11-19 | 2006-05-26 | Kissei Pharmaceutical Co., Ltd. | Preventive or therapeutic agent for neuropathic pain |
| EP1688141A1 (en) * | 2005-01-31 | 2006-08-09 | elbion AG | The use of flupirtine for the treatment of overactive bladder and associated diseases, and for the treatment of irritable bowel syndrome |
| US7683058B2 (en) * | 2005-09-09 | 2010-03-23 | H. Lundbeck A/S | Substituted pyrimidine derivatives |
| CN101578259A (zh) | 2006-11-28 | 2009-11-11 | 威朗国际制药公司 | 作为钾通道调节剂的1,4-二氨基双环瑞替加滨类似物 |
| US8563566B2 (en) * | 2007-08-01 | 2013-10-22 | Valeant Pharmaceuticals International | Naphthyridine derivatives as potassium channel modulators |
| CA2765678A1 (en) * | 2009-06-22 | 2010-12-29 | Christopher Blackburn | Substituted hydroxamic acids and uses thereof |
-
2008
- 2008-06-12 US US12/138,251 patent/US8367684B2/en active Active
- 2008-06-13 CA CA002689208A patent/CA2689208A1/en not_active Abandoned
- 2008-06-13 JP JP2010512399A patent/JP2010530002A/ja active Pending
- 2008-06-13 ES ES08771077T patent/ES2392774T3/es active Active
- 2008-06-13 HR HRP20120857AT patent/HRP20120857T1/hr unknown
- 2008-06-13 TW TW097122339A patent/TW200914452A/zh unknown
- 2008-06-13 EP EP08771077A patent/EP2170861B1/en not_active Not-in-force
- 2008-06-13 SI SI200830745T patent/SI2170861T1/sl unknown
- 2008-06-13 PT PT08771077T patent/PT2170861E/pt unknown
- 2008-06-13 PL PL08771077T patent/PL2170861T3/pl unknown
- 2008-06-13 MX MX2009013581A patent/MX2009013581A/es active IP Right Grant
- 2008-06-13 CN CN200880102338A patent/CN101868451A/zh active Pending
- 2008-06-13 KR KR1020107000706A patent/KR20100018618A/ko not_active Withdrawn
- 2008-06-13 WO PCT/US2008/066984 patent/WO2008157404A2/en not_active Ceased
- 2008-06-13 RU RU2010100893/04A patent/RU2010100893A/ru not_active Application Discontinuation
- 2008-06-13 BR BRPI0812564-3A2A patent/BRPI0812564A2/pt not_active Application Discontinuation
- 2008-06-13 DK DK08771077.8T patent/DK2170861T3/da active
- 2008-06-13 AU AU2008266009A patent/AU2008266009B2/en not_active Ceased
Patent Citations (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2000513014A (ja) * | 1997-03-27 | 2000-10-03 | ユハン・コーポレーション | 新規ピリミジン誘導体およびその製造方法 |
| JP2004518724A (ja) * | 2001-02-07 | 2004-06-24 | オーソーマクニール ファーマシューティカル， インコーポレイテッド | ピリドアリールフェニル・オキサゾリジノン抗菌剤、および関連の組成物および方法 |
| WO2003066099A1 (en) * | 2002-02-05 | 2003-08-14 | Yamanouchi Pharmaceutical Co., Ltd. | 2,4,6-triamino-1,3,5-triazine derivative |
| JP2004002309A (ja) * | 2002-02-12 | 2004-01-08 | Pfizer Inc | 非ペプチドＧｎＲＨ剤、医薬組成物、及びそれらの使用方法 |
| WO2005066171A1 (en) * | 2003-12-24 | 2005-07-21 | Renovis, Inc. | Bicycloheteroarylamine compounds as ion channel ligands and uses thereof |
| WO2006006741A1 (ja) * | 2004-07-15 | 2006-01-19 | Japan Tobacco Inc. | 縮合ベンズアミド化合物及びバニロイド受容体１型(ｖｒ１)活性阻害剤 |
| WO2006029623A1 (en) * | 2004-09-13 | 2006-03-23 | H. Lundbeck A/S | Substituted aniline derivatives |
| WO2006034402A2 (en) * | 2004-09-21 | 2006-03-30 | Synta Pharmaceutical Corp. | Compounds for inflammation and immune-related uses |
| WO2006092143A1 (en) * | 2005-03-03 | 2006-09-08 | H. Lundbeck A/S | Substituted pyridine derivatives |
| WO2007050348A2 (en) * | 2005-10-21 | 2007-05-03 | Merck & Co., Inc. | Potassium channel inhibitors |
| WO2008024398A2 (en) * | 2006-08-23 | 2008-02-28 | Valeant Pharmaceuticals International | Derivatives of 4-(n-azacycloalkyl) anilides as potassium channel modulators |
Non-Patent Citations (1)
| Title |
|---|
| JPN6013028424; Ｂｅｅｂｙ Ｍ． Ｈ． ｅｔ ａｌ: Ｊｏｕｒｎａｌ ｏｆ ｔｈｅ Ｃｈｅｍｉｃａｌ Ｓｏｃｉｅｔｙ , 1949, ｐｐ．１７９９-１８０３ * |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2010535244A (ja) * | 2007-08-01 | 2010-11-18 | バレアント ファーマシューティカルズ インターナショナル | カリウムチャネル調節因子としてのナフチリジン誘導体 |
| JP2010536771A (ja) * | 2007-08-13 | 2010-12-02 | バレアント ファーマシューティカルズ インターナショナル | カリウムチャネルモジュレーターとしての５−アミノ−４，６−二置換インドールおよび５−アミノ−４，６−二置換インドリンの誘導体 |
| JP2021525241A (ja) * | 2018-05-22 | 2021-09-24 | シャンハイ ジムン バイオファーマ, インコーポレーテッドShanghai Zhimeng Biopharma Inc. | カリウムチャネル調節剤としてのｐ−ジアミノベンゼン誘導体、その製造方法およびその医薬における使用 |
| JP7294681B2 (ja) | 2018-05-22 | 2023-06-20 | シャンハイ ジムン バイオファーマ，インコーポレーテッド | カリウムチャネル調節剤としてのｐ－ジアミノベンゼン誘導体、その製造方法およびその医薬における使用 |
| JP2025504538A (ja) * | 2022-01-25 | 2025-02-12 | シャンハイ ジムン バイオファーマ，インコーポレーテッド | カリウムチャネル調節剤としてのアミド系化合物およびその製造と使用 |
| JP7823941B2 (ja) | 2022-01-25 | 2026-03-04 | シャンハイ ジムン バイオファーマ，インコーポレーテッド | カリウムチャネル調節剤としてのアミド系化合物およびその製造と使用 |
Also Published As
| Publication number | Publication date |
|---|---|
| CA2689208A1 (en) | 2008-12-24 |
| WO2008157404A3 (en) | 2009-02-19 |
| US20080318979A1 (en) | 2008-12-25 |
| AU2008266009B2 (en) | 2013-06-06 |
| PL2170861T3 (pl) | 2013-01-31 |
| PT2170861E (pt) | 2012-09-06 |
| KR20100018618A (ko) | 2010-02-17 |
| RU2010100893A (ru) | 2011-07-20 |
| AU2008266009A1 (en) | 2008-12-24 |
| BRPI0812564A2 (pt) | 2015-02-10 |
| WO2008157404A2 (en) | 2008-12-24 |
| DK2170861T3 (da) | 2012-11-26 |
| US8367684B2 (en) | 2013-02-05 |
| ES2392774T3 (es) | 2012-12-13 |
| HRP20120857T1 (hr) | 2012-11-30 |
| SI2170861T1 (sl) | 2012-12-31 |
| EP2170861A2 (en) | 2010-04-07 |
| EP2170861B1 (en) | 2012-08-29 |
| MX2009013581A (es) | 2010-01-26 |
| TW200914452A (en) | 2009-04-01 |
| CN101868451A (zh) | 2010-10-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010530002A (ja) | カリウムチャネルモジュレーターとしての４−（ｎ−アザシクロアルキル）アニリドの誘導体 | |
| KR101883125B1 (ko) | 피리딘 아미도피리미딘 유도체, 그의 제조 방법 및 용도 | |
| KR102405452B1 (ko) | 섬유아세포 성장 인자 수용체의 억제 | |
| EP2464647B1 (en) | Azaindazoles as btk kinase modulators and use thereof | |
| CN105503827B (zh) | Egfr抑制剂及其制备方法和用途 | |
| JP7627967B2 (ja) | Ｃｄ７３阻害剤、その製造方法と応用 | |
| CA2619462A1 (en) | Phosphodiesterase 10 inhibitors | |
| KR20080043840A (ko) | 히스타민 ｈ4 수용체 활성의 조정자로서 2-아미노피리미딘유도체 | |
| Bowman et al. | Synthesis of heteroarenes using cascade radical cyclisation via iminyl radicals | |
| KR102566834B1 (ko) | 코판리십 및 그의 디히드로클로라이드 염의 합성 | |
| AU2005282721A1 (en) | 4-substituted 4, 6-dialkoxy-cinnoline derivatives as phospodiesterase 10 inhibitors for the treatment of psychiatric or neurological syndroms | |
| CN109867676A (zh) | 一种吡咯并嘧啶衍生的化合物、药物组合物以及其用途 | |
| WO2005066171A1 (en) | Bicycloheteroarylamine compounds as ion channel ligands and uses thereof | |
| CN116157128B (zh) | 吡唑并哒嗪酮化合物、其药物组合物及其用途 | |
| CA3196068A1 (en) | 2,3-dihydro-1h-pyrrolo[3,2-b]pyridine derivative, preparation method therefor, and application thereof | |
| CN111683662A (zh) | 取代嘧啶类化合物及其药物组合物和治疗方法 | |
| CA2709650A1 (en) | 4-aminopyrimidine derivatives as histamine h4 receptor antagonists | |
| JP2022500476A (ja) | 環状ジヌクレオチド類似体、その医薬組成物及び使用 | |
| RU2329260C1 (ru) | Способ получения 2-анилинопиримидинов или их солей (варианты) | |
| CN115362155B (zh) | 芳胺类衍生物及其制备方法和医药用途 | |
| CN114634491B (zh) | 一类抑制rna解旋酶dhx33的多环化合物 | |
| EP2905024A1 (en) | Pyrido[2,3-d]pyrimidine-7(8H)-one derivatives for the treatment of infections caused by Flaviviridae | |
| CN111606888A (zh) | 吡咯类衍生物及其制备方法与应用 | |
| CN117062809B (zh) | 双环杂环fgfr4抑制剂，包含其的药物组合物和制剂，及其应用 | |
| TW202430168A (zh) | Tyk2假激酶配體及其用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110610 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20110610 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120529 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20131210 |